1.Possible Risk Factors for Bone Marrow Fibroplasia in Patients with Polycythemia Vera.
De-Hao WANG ; Pei ZHAO ; Zi-Qing WANG ; Er-Peng YANG ; Yu-Meng LI ; Ji-Cong NIU ; Yi CHEN ; Ke CHEN ; Ming-Jing WANG ; Wei-Yi LIU ; Yan LYU ; Xiao-Mei HU
Journal of Experimental Hematology 2023;31(6):1780-1786
OBJECTIVE:
To understand the biological characteristics of polycythemia vera (PV) patients with myeloid fibroplasia, and further analyze the risk factors affecting myeloid fibroplasia in PV patients, so as to provide ideas for predicting the occurrence of myeloid fibroplasia in PV patients.
METHODS:
Forty patients with PV in the Department of Hematology, Xiyuan Hospital of China Academy of Chinese Medical Sciences were collected and divided into two groups, with (hyperplasia group) and without (Non-proliferative group) hyperplasia of bone marrow fibers. The differences of basic clinical characteristics, blood routine, biochemistry, bone marrow cells, coagulation function and other indicators between the two groups were compared, and the independent risk factors affecting the proliferation of bone marrow fibrous tissue in PV patients were further analyzed by multivariate regression.
RESULTS:
Compared with Non-proliferative group, the JAK2 mutation rate (95% vs 70%,P=0.037), eosinophilic cell count (0.19 vs 0.11, P=0.047) and eosinophilic percentage (1.84 vs 1.27, P=0.001) in PV patients with hyperplasia were significantly increased, triglycerides (1.55 vs 1.91, P=0.038) and low-density lipoprotein (1.50 vs 3.08, P=0.000) were significantly reduced, bone marrow hematopoietic volume (0.85 vs 0.6, P=0.001), granulocyte/erythrocyte ratio (3.40 vs 1.89, P=0.033), lymphocyte/erythrocyte ratio (0.60 vs 0.42, P=0.033), and granulocyte+lymphocyte/erythrocyte ratio (3.72 vs 2.37, P=0.026) were significantly increased, thrombin time (18.84 vs 18.12, P=0.043) was significantly prolonged. Multivariate regression analysis results showed that peripheral blood eosinophil ≥2% and low-density lipoprotein ≤2 mmol/L were independent risk factors for bone marrow fibrous tissue hyperplasia in PV patients (P<0.05).
CONCLUSION
Increased proportion of peripheral blood eosinophils and decreased low density lipoprotein are risk factors for bone marrow fibrous tissue hyperplasia in PV patients.
Humans
;
Bone Marrow/pathology*
;
Polycythemia Vera
;
Hyperplasia/pathology*
;
Granulocytes/pathology*
;
Janus Kinase 2/genetics*
;
Risk Factors
;
Lipoproteins, LDL
;
Polycythemia/pathology*
2.A rat model of high altitude polycythemia rapidly established by hypobaric hypoxia exposure.
Pei-Bing LI ; Hong-Jing NIE ; Wei LIU ; Bing-Nan DENG ; Hui-Li ZHU ; Rui-Feng DUAN ; Zhao-Li CHEN ; Hai WANG
Chinese Journal of Applied Physiology 2014;30(6):526-531
OBJECTIVETo investigate the effects of simple hypobaric hypoxia on parameters of hematology and blood rheology in order to establish a rat model of simulated high altitude polycythemia (HAPC) for the study of pathophysiologic mechanisms and medical prevention and treatment of HAPC.
METHODSForty-eight male Wistar rats were randomly divided into three normal control groups and three hypoxia model groups. Normal control group rats were bred in normoxia conditions, and hypoxia group rats were subjected to hypoxic exposure for 8 hours per day at simulated 5 500 m high altitude in a hypobaric chamber. After hypoxic exposure for 2, 4, 12 weeks, one group of normal control and hypoxia model rats were killed and blood was collected, respectively. Then parameters of erythrocyte and blood rheology were examined.
RESULTSMucous membrane of hypoxia model rats showed obviously cyanosis after 2 weeks hypoxic exposure. Hemoglobin concentration of hypoxia model rats were beyond 210 g/L after 2 weeks, 4 weeks and 12 weeks hypoxia exposure and significantly increased than that of normal control rats respectively. Besides, RBC counts, hematocrit, whole blood viscosity, erythrocyte aggregation index of hypoxia model rats were all notably higher than those of normal control rats respectively.
CONCLUSIONA rat model of high altitude polycythemia can be rapidly established by hypobaric hypoxia exposure at simulated 5 500 m high altitude for 8 hours daily.
Altitude ; Altitude Sickness ; Animals ; Disease Models, Animal ; Erythrocyte Count ; Hematocrit ; Hypoxia ; Male ; Polycythemia ; pathology ; Rats ; Rats, Wistar
3.Expressions of c-mpl proteins on CD34+ bone marrow cells and platelets of the patients with polycythemia vera.
Jie BAI ; Zong-Hong SHAO ; Jun SHI ; Hai-Rong JIA ; Juan SUN
Journal of Experimental Hematology 2007;15(5):1061-1064
The objective of this study was to investigate the expressions of TPO receptor (c-mpl) proteins on CD34 positive bone marrow cells (CD34+ BMCs), platelets and the expression of c-mpl mRNA in bone marrow cells of the patients with polycythemia vera (PV). The expressions of c-mpl proteins on CD34+ bone marrow hematopoietic cells of 13 PV patients and 15 normal controls were assessed by bicolor flow cytometry and the expressions of c-mpl proteins on platelets of 15 PV patients and 15 normal controls were assessed by monocolor flow cytometry, and the expressions of c-mpl mRNA in bone marrow hematopoietic cells (BMHCs) were assessed by RT-PCR. The results showed that no difference was found between the expression of c-mpl proteins on CD34+ BMHCs of PV patients (0.99% +/- 0.14%) and that of normal controls (0.92% +/- 0.12%) (p > 0.05). There was no difference too between the expression of c-mpl protein on platelets in PV patients (20.33% +/- 4.84%) and that in normal controls (23.50% +/- 3.64%) (p > 0.05). No difference between the expression of c-mpl mRNA in BMHCs of PV patients and that in normal controls was seen. In conclusion, the expressions of c-mpl proteins on CD34+ BMHCs, platelets and c-mpl mRNA in BMHCs of PV patients were not obviously abnormal.
Antigens, CD34
;
analysis
;
Blood Platelets
;
metabolism
;
Bone Marrow Cells
;
metabolism
;
pathology
;
Hematopoietic Stem Cells
;
metabolism
;
pathology
;
Humans
;
Polycythemia Vera
;
genetics
;
metabolism
;
RNA, Messenger
;
metabolism
;
Receptors, Thrombopoietin
;
metabolism
4.Clinical analysis of 185 patients with polycythemia vera.
Jie BAI ; Zonghong SHAO ; Liping JING ; Hong LIU ; Jun SHI ; Mingfeng ZHAO ; Rong FU ; Guangsheng HE ; Juan SUN ; Hairong JIA ; Linsheng QIAN ; Tianying YANG ; Chongli YANG
Chinese Journal of Hematology 2002;23(11):578-580
OBJECTIVETo understand the clinical feature and natural course of polycythemia vera (PV).
METHODSThe clinical symptoms, signs, laboratory examination and prognosis of 185 patients with PV were analysed.
RESULTSThere are 122 males and 63 females. The mean age was (52.7 +/- 14.1) years. The mean hemoglobin level was (208.3 +/- 21.2) g/L. Pancytosis was displayed in 74 (40%) cases, excess of red blood cells in 33 (17.8%), excess of red blood cells and granulocytes in 67 (36.2%) and excess of red blood cell and platelets in 11 (5.9%). Splenomegaly was found in 123 (66.5%) patients and hepatomegaly in 30 (16.2%). Quantitative assess of serum Epo was done in 25 patients. The level was low in 16 (64.2%) and normal in 9 (36.0%). Hematopoietic progenitor culture yields was elevated in 11 patients, endogenous erythroid colonies (EEC) formation was found in 10 cases (90.9%). Eighty two patients (44.3%) had 101 attacks of vascular thrombotic incidents, 7 patients developed myelofibrosis (MF). Secondary cancer occurred in 1 patient. Two patients died of thrombosis.
CONCLUSIONPV is an elderly adult myeloproliferative disease with a high frequency of thrombosis. EEC can be found out in PV patients. The serum Epo level is not increased in PV patients. The main sequelae of PV is MF.
Adult ; Aged ; Erythrocyte Count ; Female ; Hemoglobins ; metabolism ; Hepatomegaly ; etiology ; Humans ; Leukocyte Count ; Male ; Middle Aged ; Polycythemia Vera ; blood ; complications ; pathology ; Primary Myelofibrosis ; etiology ; Splenomegaly ; etiology ; Thrombosis ; etiology
5.Effect of erlotinib on proliferation and differentiation of JAK2V617F-positive cells in vitro.
Yuan-Yuan REN ; Ling-Yan ZHANG ; Ying LI
Journal of Experimental Hematology 2012;20(2):368-371
The aim of this study was to investigate the effect of erlotinib on proliferation and differentiation of JAK2V617F-positive cells in vitro, and to provide experimental evidence of erlotinib for potential target therapy in polycythemia vera. Colony forming assays were used to detect the effect of erlotinib on differentiation of hematopoietic progenitor cells from bone marrow of polycythemia vera patients, and MTT method was used to measure the proliferation of HEL cell line containing the JAK2V617F mutation. The results showed that erlotinib 5 µmol/L inhibited the differentiation of JAK2V617F-positive hematopoietic progenitor cells into hematopoietic colonies in vitro, while it had almost no effect on normal hematopoietic progenitor cells from the patients. Erlotinib had inhibitory effect on the proliferation of HEL cell line in a dose dependent manner. The IC(50) was 4.1 µmol/L. It is concluded that erlotinib can inhibit proliferation and differentiation of JAK2V617F-positive cells to a certain extent in vitro.
Cell Differentiation
;
drug effects
;
Cell Proliferation
;
drug effects
;
Cells, Cultured
;
Erlotinib Hydrochloride
;
Hematopoietic Stem Cells
;
cytology
;
Humans
;
Janus Kinase 2
;
metabolism
;
Polycythemia Vera
;
pathology
;
Quinazolines
;
pharmacology
6.Apoptosis and proliferation of CD34 positive bone marrow cells in patients with polycythemia vera.
Jie BAI ; Zong-hong SHAO ; Hong LIU ; Jun SHI ; Guang-sheng HE ; Yan-ran CAO ; Mei-feng TU ; Zhen-zhu CUI ; Hai-rong JIA ; Juan SUN ; Lin-sheng QIAN ; Tian-ying YANG ; Chong-li YANG
Chinese Journal of Hematology 2004;25(4):195-197
OBJECTIVETo study the apoptosis and proliferation of CD(34) positive (CD(34)(+)) bone marrow cells (BMC) in patients with polycythemia vera (PV).
METHODSThe expression of Annexin V and Ki67 of the CD(34)(+) BMC in 20 PV patients and control cases [10 essential thrombocythemia (ET), 12 normal persons] were assessed by bicolor flow cytometry (FCM), and the correlation between apoptosis and clinical situation was analysed in PV patients.
RESULTSThe Annexin V expressions of CD(34)(+) BMC were (15.96 +/- 1.45)% in PV patients and (15.53 +/- 1.76)% in ET patients which were lower than that in normal subjects [(23.61 +/- 3.89)%, (P < 0.05)]. The Ki67 expression of CD(34)(+) BMC was (48.79 +/- 11.68)% in PV patients and (49.60 +/- 9.98)% in ET patients, which were significantly higher than that in normal controls (33.87 +/- 6.82)%. The ratio of apoptosis/proliferation in PV patients was 0.33 +/- 0.10 and in ET patients 0.32 +/- 0.02 which were significantly lower than that in normal controls 0.72 +/- 0.11 (P < 0.01). The apoptosis of CD(34)(+) BMC was negatively correlated with the hemoglobin (Hb) levels (r = -0.481, P = 0.037), white blood cells (WBC) (r = -0.538, P = 0.026) and the numbers of endogenous erythroid colony (EEC) (r = -0.632, P = 0.50), and the ratio of apoptosis/proliferation was negatively correlated with the Hb (r = -0.537, P = 0.018) and WBC (r = -0.667, P = 0.003) in PV patients.
CONCLUSIONThere were lower apoptosis and higher proliferation in CD(34)(+) BMC of PV patients. Lower apoptosis was correlated with the severity of the disease.
Adult ; Annexin A5 ; analysis ; Antigens, CD34 ; analysis ; Apoptosis ; Bone Marrow Cells ; cytology ; Cell Division ; Female ; Humans ; Male ; Middle Aged ; Polycythemia Vera ; pathology
7.Clinical and laboratory features compared between JAK2 exon12 and JAK2 V617F mutated polycythemia vera.
Dan LIU ; Pei Hong ZHANG ; Ze Feng XU ; Jiao MA ; Tie Jun QIN ; Shi Qiang QU ; Xiu Juan SUN ; Bing LI ; Li Juan PAN ; Yu Jiao JIA ; Zhi Jian XIAO
Chinese Journal of Hematology 2022;43(2):107-114
Objective: To compare clinical and laboratory features between JAK2 exon12 and JAK2 V617F mutated polycythemia vera (PV) . Method: We collected data from 570 consecutive newly-diagnosed subjects with PV and JAK2 mutation, and compared clinical and laboratory features between patients with JAK2 exon12 and JAK2 V617F mutation. Results: 543 (95.3%) subjects harboured JAK2 V617F mutation (JAK2 V617F cohort) , 24 (4.2%) harboured JAK2 exon12 mutations (JAK2 exon12 cohort) , and 3 (0.5%) harboured JAK2 exon12 and JAK2 V617F mutations. The mutations in JAK2 exon12 including deletion (n=10, 37.0%) , deletion accompanied insertion (n=10, 37.0%) , and missense mutations (n=7, 25.9%) . Comparing with JAK2 V617F cohort, subjects in JAK2 exon12 cohort were younger [median age 50 (20-73) years versus 59 (25-91) years, P=0.040], had higher RBC counts [8.19 (5.88-10.94) ×10(12)/L versus 7.14 (4.11-10.64) ×10(12)/L, P<0.001] and hematocrit [64.1% (53.7-79.0%) versus 59.6% (47.2%-77.1%) , P=0.001], but lower WBC counts [8.29 (3.2-18.99) ×10(9)/L versus 12.91 (3.24-38.3) ×10(9)/L, P<0.001], platelet counts [313 (83-1433) ×10(9)/L versus 470 (61-2169) ×10(9)/L, P<0.001] and epoetin [0.70 (0.06-3.27) versus 1.14 (0.01-10.16) IU/L, P=0.002] levels. We reviewed bone marrow histology at diagnosis in 20 subjects with each type of mutation matched for age and sex. Subjects with JAK2 exon12 mutations had fewer loose megakaryocyte cluster (40% versus 80%, P=0.022) compared with subjects with JAK2 V617F. The median follow-ups were 30 months (range 4-83) and 37 months (range 1-84) for cohorts with JAK2 V617F and JAK2 exon12, respectively. There was no difference in overall survival (P=0.422) and thrombosis-free survival (P=0.900) . Conclusions: Compared with patients with JAK2 V617F mutation, patients with JAK2 exon12 mutation were younger, and had more obvious erythrocytosis and less loose cluster of megakaryocytes.
Adult
;
Aged
;
Aged, 80 and over
;
Bone Marrow/pathology*
;
Exons
;
Humans
;
Janus Kinase 2/genetics*
;
Middle Aged
;
Mutation
;
Mutation, Missense
;
Polycythemia Vera/genetics*
;
Young Adult
8.Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis.
Jie BAI ; Yang-Ping XUE ; Lei ZHANG ; Chun-Hua LI ; Dong-Mei FAN ; Bin LI ; Shi-Cai XU ; Da-Peng LI ; Xiu-Juan SUN ; Bo JIANG ; Ren-Chi YANG
Journal of Experimental Hematology 2011;19(2):444-449
To evaluate the efficacy and safety of interferon-alpha-2b (IFN-α-2b) in polycythemia vera patients(PV patient) with or without post-polycythemic myelofibrosis (post-PV MF), 30 patients with mutated JAK2V617F were enrolled in this study, from which 29 patients were evaluable. The percentage of mutated JAK2V617F allele (V617F%) was evaluated by real-time polymerase chain reaction (RT-PCR) before and after treatment with IFN-α-2b. The correlation of V617F allele burden with the major clinical outcomes was studied. Adverse effects appeared in patients was observed. The results showed that the median follow-up was 24 (12 - 42) months for 29 evaluable patients. Complete hematologic response was achieved in 10%, 48%, 72% and 78% of patients after treatment for 6, 12, 24 and 36 months respectively. The detection of V617F allele burden revealed that the molecular remission of patients (V617F%) was achieved in 41%, 76%, 89% and 89% after treatment for 6, 12, 24 and 36 months respectively. Molecular complete remission (JAK2V617F undetectable) was achieved in 4 patients, lasted from 6 to 12 months after IFN-α-2b discontinuation. The decrease of V617F% in patients with post-PV MF was significantly higher than that in patients without post-PV MF (53 ± 18% vs 32 ± 22%, respectively; p = 0.031) after treatment for 12 months. PV patients had a good tolerance to IFN-α-2b. It is concluded that IFN-α-2b can decrease the mutated V617F allele burden. Patients with PV, especially with post-PV MF, can achieve molecular remission after treatment with IFN-α-2b.
Adult
;
Alleles
;
Female
;
Humans
;
Interferon-alpha
;
therapeutic use
;
Janus Kinase 2
;
genetics
;
Male
;
Middle Aged
;
Mutation
;
Polycythemia Vera
;
drug therapy
;
genetics
;
pathology
;
Primary Myelofibrosis
;
drug therapy
;
genetics
;
pathology
;
Recombinant Proteins
;
therapeutic use
9.Clinics in diagnostic imaging (146). Polycythaemia vera (PV).
Singapore medical journal 2013;54(5):289-quiz 292
A 42-year-old Chinese man presented with left-sided chest pain and splenomegaly. Full blood count revealed erythrocytosis, while plain radiograph and computed tomography of the abdomen and pelvis revealed hepatosplenomegaly with splenic infarction. Further workup confirmed the diagnosis of polycythaemia vera. Clinical and imaging features of polycythaemia vera, as well as the potential pitfalls in image interpretation, are discussed in this article.
Adult
;
Brain
;
pathology
;
Cerebral Infarction
;
complications
;
diagnosis
;
Diagnostic Imaging
;
methods
;
Humans
;
Liver
;
pathology
;
Male
;
Middle Aged
;
Polycythemia Vera
;
diagnosis
;
diagnostic imaging
;
Radiography, Abdominal
;
methods
;
Seizures
;
diagnosis
;
Splenomegaly
;
diagnosis
;
Tomography, X-Ray Computed
;
methods
;
Venous Thrombosis
;
diagnosis
10.Burden of abnormal hematopoietic clone in patients with myelodysplastic syndromes.
Hua-Quan WANG ; Zong-Hong SHAO ; Jun SHI ; Yan-Ran CAO ; Hong LIU ; Jie BAI ; Mei-Feng TU ; Li-Ming XING ; Zhen-Zhu CUI ; Shi-He LIU ; Jun SUN ; Hai-Rong JIA ; Tian-Ying YANG
Chinese Medical Sciences Journal 2006;21(2):99-103
OBJECTIVETo investigate the role of the burden of abnormal hematopoietic clone in the development of myelodysplastic syndromes (MDS).
METHODSThe ratio of the bone marrow cells with abnormal chromosomes to the total counted bone marrow cells was regarded as the index of MDS clone burden. The disease severity related parameters including white blood cell count, hemoglobin, platelet count, lactate dehydrogenase level, bone marrow blast, myeloid differentiation index, micromegakaryocyte, transfusion, interleukin-2, tumor necrosis factor (TNF), CD4+ and CD8+ T cells of MDS patients were assayed, and the correlations between those parameters and MDS clone burden were also analyzed.
RESULTSThe clone burden of MDS patients was 67.4% +/- 36.2%. MDS clone burden positively correlated with bone marrow blasts (r = 0.483, P < 0.05), negatively with hemoglobin level (r = -0.445, P < 0.05). The number of blasts, hemoglobin, and erythrocytes in high clone burden (> 50%) and low clone burden ( < or = 50%) groups were 7.78% +/- 5.51% and 3.45% +/- 3.34%, 56.06 +/- 14.28 g/L and 76.40 +/- 24.44 g/L, (1.82 +/- 0.48) x 10(12)/L and (2.32 +/- 0.66) x 10(12)/L, respectively (all P < 0.05). CD4+ T lymphocytes of MDS patients and normal controls were (0.274 +/- 0.719) x 10(9)/L and (0.455 +/- 0.206) x 10(9)/L, respectively (P < 0.05). CD8+ T lymphocytes of MDS patients and normal controls were (0.240 +/- 0.150) x 10(9)/L and (0.305 +/- 0.145) x 10(9)/L, respectively. The serum level of interleukin-2 of MDS patients (6.29 +/- 3.58 ng/mL) was significantly higher than normal control (3.11 +/- 1.40 ng/mL, P < 0.05). The serum level of TNF of MDS patients and normal control group were 2.42 +/- 1.79 ng/mL and 1.68 +/- 0.69 ng/mL, respectively. The ratio of CD4 to CD8 was higher in high clone burden MDS patients (1.90 +/- 0.52) than that in low clone burden patients (0.97 +/- 0.44, P < 0.05).
CONCLUSIONThe quantitive clonal karyotype abnormalities and deficient T cell immunity are important parameters for evaluating MDS severity and predicting its progression.
Adolescent ; Adult ; Aged ; Bone Marrow Cells ; pathology ; Case-Control Studies ; Chromosome Aberrations ; Female ; Hematopoiesis ; genetics ; Hematopoietic Stem Cells ; pathology ; Humans ; Male ; Middle Aged ; Myelodysplastic Syndromes ; blood ; genetics ; pathology ; Neoplastic Stem Cells ; pathology ; Polycythemia ; genetics ; pathology ; T-Lymphocyte Subsets ; pathology ; Young Adult